LAPTOP-PPI试验数据表1：消化性溃疡和胃食管反流病药物处方不当

数据集获取（Figshare）

• 源站标题：Data Sheet 1_Inappropriate prescribing of drugs for peptic ulcer and gastro-esophageal reflux disease remains a matter of concern: Results from the LAPTOP-PPI cluster randomized trial.docx
• DOI：10.3389/fphar.2024.1430879.s001
• 发布日期：2025-01-03
• 文件数：1 个
• 文件总体积：1.30 MB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Inappropriate_prescribing_of_drugs_for_peptic_ulcer_and_gastro-esophageal_reflux_disease_remains_a_matter_of_concern_Results_from_the_LAPTOP-PPI_cluster_randomized_trial_docx/28128734

命令行下载

curl -L -o "Data Sheet 1_Inappropriate prescribing of drugs for peptic ulcer and gastro-esophageal reflux disease remains a matter of concern: Results from the LA.docx" "https://ndownloader.figshare.com/files/51460118"

文件清单

• Data Sheet 1_Inappropriate prescribing of drugs for peptic ulcer and gastro-esophageal reflux disease remains a matter of concern: Results from the LA.docx（1.30 MB）

文件总体积 1.30 MB（源站 API 实测）。

数据说明

BackgroundProton pump inhibitors (PPIs) are among the most commonly and inappropriately prescribed drugs by general practitioners (GPs), resulting in increased risk of adverse outcomes for patients and in avoidable costs for Italy’s National Health Service (NHS). This study aims to assess the effectiveness of a low-cost and easily implementable informative intervention directed at GPs to enhance the appropriate prescription of PPIs.
MethodsThe LAPTOP-PPI study is a pragmatic, cluster-randomized controlled trial designed to improve the appropriateness of PPI prescriptions among community-dwelling individuals aged ≥65 years. In June 2021, GPs in the Local Health Units (LHUs) of Bergamo (Northern Italy) and Caserta (Southern Italy) were randomly allocated to either an intervention group (summary reports on prescribing habits, scientific documents on the Italian Medicine Agency’s therapeutic indications, strategies for PPI de-prescribing, along with educational materials for patients), and a control group (standard practice). PPI appropriateness was assessed through an algorithm specifically designed and based on NHS prescription appropriateness and reimbursement criteria. Intervention efficacy was evaluated by comparing data from the baseline period (July 1 to 31 December 2019) with those from the follow-up period (July 1 to 31 December 2021), 6 months after randomization. The analysis was performed on the intention-to-treat principle and according to GP level. To estimate the effectiveness of the intervention, we used a difference-in-differences (DID) approach.
ResultsOverall, 942 GPs (540 from Bergamo and 402 from Caserta LHUs) were included in the analysis. At baseline, 171,978 patients aged ≥65 received drug prescriptions for acid-related diseases and were assessable for evaluation of appropriateness. At follow-up, this number was 137,699. The overall inappropriateness rate at baseline among GPs included in the analysis was 57.4% (std.dev. 8.4%) in the intervention arm and 57.6% (std.dev. 8.8%) in the control arm; 6 months after the intervention delivery, they were 59.2% (std.dev. 8.0%) and 58.5% (std.dev. 7.3%), respectively.
ConclusionGiven their widespread u

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fphar.2024.1430879.s001（source: https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Inappropriate_prescribing_of_drugs_for_peptic_ulcer_and_gastro-esophageal_reflux_disease_remains_a_matter_of_concern_Results_from_the_LAPTOP-PPI_cluster_randomized_trial_docx/28128734）。